Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy is a research paper published in ESMO Open (2023). On theSindex it has a DataRank of 0. It has been cited 103 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston
Grant: UL1 TR000371
Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy
Grant: 1U01 CA180964
National Cancer Institute
Grant: R01CA242845
National Cancer Institute
Grant: R01CA273168
Cancer Prevention and Research Institute of Texas
Grant: RP1100584
University of Texas MD Anderson Cancer Center
Grant: P30 CA016672
NCI NIH HHS
Grant: U01 CA180964
National Center for Advancing Translational Sciences
National Institutes of Health
FWCI
9.55
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study
Additional file 1 of RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study
Additional file 2 of RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study
Additional file 2 of RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study
Additional file 1 of Combined therapy of dabrafenib and an anti-HER2 antibody–drug conjugate for advanced BRAF-mutant melanoma
Additional file 1 of Combined therapy of dabrafenib and an anti-HER2 antibody–drug conjugate for advanced BRAF-mutant melanoma